Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas

Por Loni, L, Tacca, M Del, Danesi, R
Publicado em 2001

Imatinib administration in two patients with liver metastases from GIST and severe jaundice

Por De Pas, T, Danesi, R, Catania, C, Curigliano, G, de Braud, F
Publicado em 2003

Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile

Por Giovannetti, E, Mey, V, Danesi, R, Basolo, F, Barachini, S, Deri, M, Del Tacca, M
Publicado em 2005

Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells

Por Bocci, G, Fioravanti, A, Orlandi, P, Bernardini, N, Collecchi, P, Del Tacca, M, Danesi, R
Publicado em 2005

Synergistic interaction between PPAR ligands and salbutamol on human bronchial smooth muscle cell proliferation

Por Fogli, S, Stefanelli, F, Picchianti, L, Del Re, M, Mey, V, Bardelli, C, Danesi, R, Breschi, MC
Publicado em 2013

Involvement of basic fibroblast growth factor in suramin-induced inhibition of V79/AP4 fibroblast cell proliferation.

Por Bernardini, N., Giannessi, F., Bianchi, F., Dolfi, A., Lupetti, M., Citti, L., Danesi, R., Del Tacca, M.
Publicado em 1993

Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells

Por Paolo, A Di, Danesi, R, Caputo, S, Macchia, M, Lastella, M, Boggi, U, Mosca, F, Marchetti, A, Tacca, M Del
Publicado em 2001

Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane.

Por Danesi, R., Del Bianchi, S., Soldani, P., Campagni, A., La Rocca, R. V., Myers, C. E., Paparelli, A., Del Tacca, M.
Publicado em 1993

Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumourcells

Por Paolo, A Di, Danesi, R, Nardini, D, Bocci, G, Innocenti, F, Fogli, S, Barachini, S, Marchetti, A, Bevilacqua, G, Tacca, M Del
Publicado em 2000

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients

Por Mey, V, Giovannetti, E, Braud, F De, Nannizzi, S, Curigliano, G, Verweij, F, De Cobelli, O, Pece, S, Del Tacca, M, Danesi, R
Publicado em 2006

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib

Por Bocci, G, Falcone, A, Fioravanti, A, Orlandi, P, Di Paolo, A, Fanelli, G, Viacava, P, Naccarato, A G, Kerbel, R S, Danesi, R, Del Tacca, M, Allegrini, G
Publicado em 2008

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients

Por Allegrini, G, Falcone, A, Fioravanti, A, Barletta, M T, Orlandi, P, Loupakis, F, Cerri, E, Masi, G, Di Paolo, A, Kerbel, R S, Danesi, R, Del Tacca, M, Bocci, G
Publicado em 2008

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide

Por Orlandi, P, Fontana, A, Fioravanti, A, Di Desidero, T, Galli, L, Derosa, L, Canu, B, Marconcini, R, Biasco, E, Solini, A, Francia, G, Danesi, R, Falcone, A, Bocci, G
Publicado em 2013

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

Por Loupakis, F, Cremolini, C, Fioravanti, A, Orlandi, P, Salvatore, L, Masi, G, Di Desidero, T, Canu, B, Schirripa, M, Frumento, P, Di Paolo, A, Danesi, R, Falcone, A, Bocci, G
Publicado em 2011

Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma

Por Bengala, C, Guarneri, V, Giovannetti, E, Lencioni, M, Fontana, E, Mey, V, Fontana, A, Boggi, U, Del Chiaro, M, Danesi, R, Ricci, S, Mosca, F, Del Tacca, M, Conte, P F
Publicado em 2005